PreSENTIA hereditary cancer test panels can detect numerous inherited genetic changes (mutations) that could cause cancer in the future.

PreSENTIA offers an extensive portfolio of 19 hereditary cancer test panels. Each panel focuses on a set of genes that determine someone’s chances of developing a specific cancer in the future. The genetic changes in the genes that could cause cancer are inherited from parents to their children, and are present from birth. Knowing that a person carries one of these genetic mutations can help them take preventative measures and plan a more informed clinical management. As a result, early detection of cancer can be achieved – which increases the chances of successful treatment – or prevention.

WHAT IS CANCER?

Cancer is the rapid and uncontrollable growth of abnormal cells. It is the second leading cause of death, responsible for 1 out of 6 deaths globally. World Health Organization (WHO) recommends that cancer mortality can be significantly reduced by early detection and proper clinical management of cancers.

HOW DOES CANCER DEVELOP?

Cancer develops after certain genes that are responsible for keeping our body healthy undergo changes that cause them to become ‘faulty’. A cancer can be:

SPORADIC: Mutations in the genes causing cancer accumulate over time due to risk factors like tobacco, viruses (such as HPV), and environmental factors. These mutations cannot be inherited.

HEREDITARY: These mutations exist from birth. They run in families and can be passed down from parents to their children.

Inherited genetic mutations make up for 5-10% of all cancers.

WHAT SHOULD I ASK MY DOCTOR?

What are germline mutations?

Germline mutations are changes in the DNA that are inherited from parents to their children. These changes are present from birth in all the cells in the body. People with germline mutations in a cancer gene have a higher chance of developing cancer in their lifetime. If cancer develops due to a germline mutation, it is called hereditary cancer.

What is a hereditary screening test?

A hereditary screening test checks if an individual has an inherited gene mutation in a gene with high cancer susceptibility.

If you or a family member were diagnosed with hereditary cancer, or a genetic change that is linked to cancer, there's a high chance other members of your family carry the alteration as well. Each individual could be affected by cancer at different age, with wide range of severity, and by different cancer types.

WHO IS THIS TEST FOR?

Identifying the genetic change that could cause cancer in the future is useful for people with cancer in their family history, and for people suspected of having a hereditary form of cancer. This knowledge can help with better medical planning, avoiding risk factors and informing family members of their risk.

According to genetic testing guidelines* for cancer, people who might benefit from genetic testing are those that have:

  • Family members with cancer in the same side of the family
  • Multiple cancers in the same family member
  • Family members with early cancer onset
  • Family members with rare cancer types
  • A family member that has been diagnosed with a genetic mutation that has cancer susceptibility
  • Personal or family history of a hereditary cancer syndrome

Your healthcare provider will also take into account your medical family history, ethnicity and any physical findings present linked to cancer before recommending PreSENTIA to you.

* Data adapted from: American Cancer Society, National Cancer Institute, American Society of Clinical Oncology and American College of Obstetricians and Gynecologists.

HOW DOES PreSENTIA HELP ME?

PreSENTIA panels test for numerous genetic changes that are responsible for causing hereditary cancers. If you want to know more about your cancer risks, or if you have been already diagnosed with cancer and you want to know whether your cancer is hereditary, PreSENTIA can help.

  • Targeted cancer monitoring – recommended screening tests at key time intervals to detect cancer early, when treatment is more beneficial
  • Prevention of cancer by prophylactic measures
  • Actionable information for family members that might carry the same gene
  • Improved classification of the disease for better clinical management
  • Drug therapy (chemoprevention)

WHY CHOOSE THE PreSENTIA TEST?

  • Assesses clinically important mutations
  • Ability to select the best panel for you
  • Reliable technology
  • Short turn-around time
  • Safe and easy to perform

WHAT ARE ‘HEREDITARY CANCER SYNDROMES’?

Hereditary cancer syndromes are also known as cancer predisposing syndromes, as patients with these syndromes have an elevated risk of developing specific cancers in the future. These conditions occur when genes with critical roles in keeping our body healthy are mutated, causing a variety of symptoms and potentially affecting the quality of life. They can be inherited from one generation to the other.

Hereditary cancer syndromes characteristics

  • Multiple cancer types
  • Repeated cancers
  • Young age of cancer onset

If you have cancer in your family history and want to know about your own risk, PreSENTIA can help. By identifying the mutated genes that could cause hereditary cancer syndromes, PreSENTIA can provide information that could help in clinical management. If you have been diagnosed with cancer and have any of the above characteristics, you might also have a hereditary cancer syndrome. Identifying this can help reveal how and why your cancer was caused.

HOW ACCURATE IS IT?

TARGETED TECHNOLOGY

By focusing only on the genetic changes tested, PreSENTIA is accurate and precise.

HIGH READ DEPTH

PreSENTIA analyzes the locations of the genetic changes hundreds of times, making the test results more sensitive and reliable.

WHAT DOES IT TEST FOR?

HEREDITARY CANCER PANELS

  • BREAST & GYNAECOLO­GICAL

    26

    BREAST/GYNAECOLOGICAL HEREDITARY GENE PANEL

    Description

    The PreSentia hereditary breast/gynaecological cancer panel tests for numerous inherited genetic alterations that could cause Breast, Ovarian or Endometrial cancers in the future. Identifying these mutations is empowering for healthcare providers and for patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for breast/gynaecological cancers are those that have:

    • More than 2 family members with cancer in the same side of the family
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member with multiple cancers
    • A family member that has been diagnosed with a genetic mutation that has cancer susceptibility
    • History of previous malignancies

    TAT:
    14 days
    Sample:
    Buccal Swab
    No of Genes Tested:
    26
    No of related hereditary cancer syndromes:
    10

    Genes Tested

    ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53

    Hereditary Cancer Syndromes associated with this panel:

    • Hereditary Breast & Ovarian cancer syndrome (BRCA1, BRCA2) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Melanoma, Stomach, Esophagus)
    • Li-Fraumeni syndrome (TP53) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain tumors, Lung, Leukemia)
    • Li-Fraumeni syndrome 2 (CHEK2) (Associated cancers: Breast, Sarcomas, Brain tumors)
    • PTEN Hamartoma syndrome (PTEN) (Associated cancers: Breast, Endometrial, Colorectal, Melanoma, Renal)
    • Peutz-Jeghers syndrome (STK11) (Associated cancers: Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic)
    • Hereditary diffuse gastric syndrome (CDH1) (Associated cancers: Stomach, Breast)
    • MUTYH-associated polyposis syndrome (MUTYH) (Associated cancers: Colorectal)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) (Associated cancers: Colorectal, Endometrial, Stomach, Ovarian, Prostate, Pancreatic, Renal)
    • Ataxia-telangiectasia syndrome (ATM) (Associated cancers: Leukemia, Lymphoma)
    • DICER 1 syndrome (DICER1) (Associated cancers: Lung, Renal, Ovarian, Thyroid cancer)
    • Polymerase Proofreading Associated syndrome (POLD1, POLE) (Associated cancers: Colorectal, Endometrial)
    • Constitutional mismatch repair syndrome (MSH2, MSH6, MLH1, PMS2) (Associated cancers: Hematologic malignancies, Brain tumors, Gastrointestinal cancers, Colorectal tumors)

  • BREAST CANCER GUIDELINES - BASED

    19

    HEREDITARY BREAST/GYNECOLOGICAL CANCER GUIDELINES-BASED PANEL

    Description

    The PreSENTIA hereditary breast cancer guidelines-based panel tests for numerous inherited genetic mutations that could cause Breast, Ovarian, Endometrial or associated cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a genetic mutation that has cancer susceptibility
    • History of previous malignancies

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    19
    No of related hereditary cancer syndromes:
    7

    Genes Tested

    ATM, CDH1, MSH6, RAD51C, BARD1, CHEK2, NBN, RAD51D, BRCA1, EPCAM, PALB2, TP53, BRCA2, MLH1, PMS2, STK11, BRIP1, MSH2, PTEN

    Hereditary Cancer Syndromes associated with this panel:

    • Hereditary Breast & Ovarian cancer syndrome (BRCA1, BRCA2) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus)
    • Li-Fraumeni syndrome (TP53) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain tumors, Lung, Leukemia)
    • Li-Fraumeni syndrome 2 (CHEK2) (Associated cancers: Breast, Sarcomas, Brain tumors)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) (Associated cancers: Colorectal, Endometrial, Stomach, Ovarian, Prostate, Pancreatic, Renal)
    • Peutz-Jeghers syndrome (STK11) (Associated cancers: Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic)
    • PTEN Hamartoma syndrome (PTEN) (Associated cancers: Breast, Endometrial, Colorectal, Melanoma, Renal)
    • Hereditary diffuse gastric syndrome (CDH1) (Associated cancers: Gastric, Breast)

  • BREAST CANCER
    HIGH-RISK

    7

    HEREDITARY BREAST CANCER HIGH-RISK PANEL

    Description

    The PreSENTIA hereditary breast cancer high-risk panel tests for numerous, high-risk inherited genetic mutations that could cause Breast, Ovarian, Endometrial or associated cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a genetic mutation that has cancer susceptibility
    • History of previous malignancies

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    7
    No of related hereditary cancer syndromes:
    5

    Genes Tested

    BRCA1,BRCA2,CDH1,PALB2,PTEN,TP53,STK11

    Hereditary Cancer Syndromes associated with this panel:

    • Hereditary Breast & Ovarian cancer syndrome (BRCA1, BRCA2) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus)
    • Li-Fraumeni syndrome (TP53) Associated cancers: (Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain tumors, Lung, Leukemia)
    • PTEN Hamartoma syndrome (PTEN) (Associated cancers: Breast, Endometrial, Colorectal, Melanoma, Renal)
    • Peutz-Jeghers syndrome (STK11) (Associated cancers: Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic)
    • Hereditary diffuse gastric syndrome (CDH1) (Associated cancers: Gastric, Breast)

  • BRCA1 / BRCA2

    2

    HEREDITARY BRCA1 / BRCA2 CANCER PANEL

    Description

    The PreSENTIA hereditary BRCA1/BRCA2 cancer panel tests for BRCA1 and BRCA2 genetic mutations that could cause specific cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers caused by mutations in the BRCA1/BRCA2 genes are those that have:

    • Several family members with cancer in the same side of the family
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a genetic mutation that has cancer susceptibility
    • History of previous malignancies

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    2
    No of related hereditary cancer syndromes:
    1

    Genes Tested

    BRCA1 ,BRCA2

    Hereditary Cancer Syndromes associated with this panel:

    • Hereditary Breast & Ovarian cancer syndrome (BRCA1, BRCA2) (Associated Cancers: Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus)

  • COLORECTAL

    17

    HEREDITARY COLORECTAL CANCER PANEL

    Description

    The PreSENTIA hereditary colorectal cancer panel tests for numerous inherited genetic mutations that could cause colorectal cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • At least one family member with genetic testing confirming genetic mutation
    • Personal history of previous malignancies

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    17
    No of related hereditary cancer syndromes:
    12

    Genes Tested

    APC, MLH1, POLE, BMPR1A, MSH2, PTEN, CDH1, MSH6, SMAD4, CHEK2, MUTYH, STK11, EPCAM, PMS2, TP53, GREM1, POLD1

    Hereditary Cancer Syndromes associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC) (Associated cancers: Gastric, Pancreatic, Colorectal, Osteomas, Small Bowel)
    • Li-Fraumeni syndrome (TP53) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain tumors, Lung, Leukemia)
    • Li-Fraumeni syndrome 2 (CHEK2) (Associated cancers: Breast, Sarcomas, Brain tumors)
    • PTEN Hamartoma syndrome (PTEN) (Associated cancers: Breast, Endometrial, Colorectal, Melanoma, Renal)
    • Peutz-Jeghers syndrome (STK11) (Associated cancers: Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic)
    • Hereditary diffuse gastric syndrome (CDH1) (Associated cancers: Gastric, Breast)
    • MUTYH-associated polyposis syndrome (MUTYH) (Associated cancer: Colorectal)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) (Associated cancers: Colorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal)
    • Polymerase Proofreading Associated syndrome (POLD1, POLE) (Associated cancers: Colorectal, Endometrial)
    • Hereditary mixed polyposis syndrome (GREM1) (Associated cancer: Colorectal)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A) (Associated cancers: Colorectal, Gastric, Pancreatic)
    • Constitutional Mismatch Repair syndrome (MSH2, MSH6, MLH1, PMS2) (Associated cancers: Hematologic malignancies, Brain tumors, Gastrointestinal cancers, Colorectal tumors)

  • COLORECTAL CANCER HIGH-RISK

    10

    Hereditary COLORECTAL CANCER HIGH-RISK PANEL

    Description

    The PreSENTIA hereditary colorectal cancer high-risk panel tests for numerous genetic mutations that could cause colorectal cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • At least one family member with genetic testing confirming genetic mutation
    • History of previous malignancies

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    10
    No of related hereditary cancer syndromes:
    6

    Genes Tested

    APC, MSH6, BMPR1A, MUTYH, EPCAM, PMS2, MLH1, SMAD4, MSH2, STK11

    Hereditary Cancer Syndromes associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC) (Associated cancers: Gastric, Pancreatic, Colorectal, Osteomas, Small Bowel)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) (Associated cancers: Colorectal, Endometrial, Stomach, Ovarian, Prostate, Pancreatic, Renal)
    • Peutz-Jeghers syndrome (STK11) (Associated cancers: Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic)
    • MUTYH-associated polyposis syndrome (MUTYH) (Associated cancer: Colorectal)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A) (Associated cancers: Colorectal, Gastric, Pancreatic)
    • Constitutional Mismatch Repair syndrome (MSH2, MSH6, MLH1, PMS2) (Associated cancers: Hematologic malignancies, Brain tumors, Gastrointestinal cancers, Colorectal)

  • COLORECTAL
    NON-POLYPOSIS

    5

    HEREDITARY NON-POLYPOSIS COLORECTAL CANCER PANEL

    Description

    The PreSENTIA hereditary colorectal non-polyposis cancer panel tests for numerous genetic mutations that could cause colorectal cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • At least one relative with genetic testing confirming genetic mutation
    • History of previous malignancies

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    5
    No of related hereditary cancer syndromes:
    2

    Genes Tested

    EPCAM, MSH6, MLH1, PMS2, MSH2

    Hereditary Cancer Syndromes associated with this panel:

    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) (Associated cancers: Colorectal, Endometrial, Stomach, Ovarian, Prostate, Pancreatic, Renal)
    • Constitutional Mismatch Repair syndrome (MSH2, MSH6, MLH1, PMS2) (Associated cancers: Hematologic malignancies, Brain tumors, Gastrointestinal cancers, Colorectal tumors)

  • COLORECTAL POLYPOSIS SYNDROME

    5

    HEREDITARY POLYPOSIS COLORECTAL CANCER PANEL

    Description

    The PreSENTIA hereditary polyposis colorectal cancer panel tests for numerous genetic mutations that could cause colorectal cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary polyposis colorectal cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • At least one family member with genetic testing confirming genetic mutation
    • History of previous malignancies

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    5
    No of related hereditary cancer syndromes:
    4

    Genes Tested

    APC, SMAD4, BMPR1A, STK11, MUTYH

    Hereditary Cancer Syndromes associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC) (Associated cancers: Gastric, Pancreatic, Colorectal, Osteomas, Small Bowel)
    • Peutz-Jeghers syndrome (STK11) (Associated cancers: Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic)
    • MUTYH-associated polyposis syndrome (MUTYH) (Associated cancer: Colorectal)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A) (Associated cancers: Colorectal, Gastric, Pancreatic)

  • MYELODYSPLASTIC SYNDROME/LEUKEMIA

    24

    PreSENTIA HEREDITARY MYELODYSPLASTIC SYNDROME / LEUKEMIA CANCER PANEL

    Description

    The PreSENTIA hereditary myelodysplastic syndrome / leukemia cancer panel tests for numerous genetic mutations that could cause blood cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary myelodysplastic syndromes or leukemias are those that have:

    • Family history of a hereditary cancer syndrome associated with leukemia
    • Personal history of a hereditary cancer syndrome associated with leukemia
    • An identical twin who developed leukemia in the first year of life
    • A family member with a confirmed genetic mutation associated with hereditary leukemia

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    24
    No of related hereditary cancer syndromes:
    6

    Genes Tested

    ATM, FANCA, FANCG, MSH6, BRCA1, FANCB, FANCI, PALB2, BRCA2, FANCC, FANCL, PMS2, BRIP1, FANCD2, FANCM, RAD51C, EPCAM, FANCE, MLH1, SLX4, ERCC4, FANCF, MSH2, TP53

    Hereditary Cancer Syndromes associated with this panel:

    • Fanconi Anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C) (Associated cancers: Leukemia, Tumors of the head and neck, Gastrointestinal)
    • Constitutional Mismatch Repair Syndrome (MSH2, MSH6, MLH1, PMS2) (Associated cancers: Hematologic malignancies, Brain tumors, Gastrointestinal cancers, Colorectal Tumors)
    • Li-Fraumeni syndrome (TP53) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain tumors, Lung, Leukemia)
    • Ataxia-telangiectasia syndrome (ATM) (Associated cancers: Leukemia, lymphoma)
    • Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) (Associated cancers: Colorectal, Endometrial, Stomach, Ovarian, Prostate, Pancreatic, Renal)
    • Hereditary Breast & Ovarian syndrome (BRCA1 & BRCA2) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Melanoma, Stomach, Esophagus)

  • GASTRIC

    14

    HEREDITARY GASTRIC CANCER PANEL

    Description

    The PreSENTIA hereditary Gastric cancer panel tests for numerous inherited genetic mutations that could cause gastric (stomach) cancers in the future. Identifying these mutations empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for gastric cancers are those that have:

    • Several family members in the same side of the family with gastric cancer
    • Personal or family history of a hereditary cancer syndrome linked to gastric cancer
    • A family member that has been diagnosed with a genetic mutation that has gastric cancer susceptibility

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    14
    No of related hereditary cancer syndromes:
    6

    Genes Tested

    APC, MSH2, SDHD, BMPR1A, MSH6, SMAD4, CDH1, PMS2, STK11, EPCAM, SDHB, TP53, MLH1, SDHC

    Hereditary Cancer Syndromes associated with this panel:

    • Hereditary diffuse gastric syndrome (CDH1) (Associated cancers: Gastric, Breast)
    • Li-Fraumeni syndrome (TP53) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain tumors, Lung, Leukemia)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) (Associated cancers: Colorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A) (Associated cancers: Colorectal, Gastric, Pancreatic)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC) (Associated cancers: Gastric, Pancreatic, Colorectal, Osteomas, Small Bowel)
    • Peutz-Jeghers syndrome (STK11) (Associated cancers: Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic)

  • PROSTATE

    15

    PreSENTIA HEREDITARY PROSTATE CANCER PANEL

    Description

    The PreSENTIA hereditary prostate cancer panel tests for numerous genetic mutations that could cause prostate cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:

    • Several first-degree family members with prostate cancer
    • Family members diagnosed with prostate cancer at young age
    • Family members diagnosed with other cancer types, including breast, ovarian and pancreatic
    • Multiple cancers in the same family member
    • At least one family member with genetic testing confirming genetic mutation.
    • History of previous malignancies

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    15
    No of related hereditary cancer syndromes:
    5

    Genes Tested

    ATM, HOXB13, PALB2, BRCA1, MLH1, PMS2, BRCA2, MSH2, PTEN, CHEK2, MSH6, RAD51D, EPCAM, NBN, TP53

    Hereditary Cancer Syndromes associated with this panel:

    • Hereditary Breast & Ovarian cancer syndrome (BRCA1, BRCA2) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) (Associated cancers: Colorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal)
    • Li-Fraumeni syndrome (TP53) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain tumors, Lung, Leukemia)
    • Li-Fraumeni syndrome 2 (CHEK2) (Associated cancers: Breast, Sarcomas, Brain tumors)
    • Ataxia-Telangiectasia syndrome (ATM) (Associated cancers: Leukemia Lymphoma)

  • PANCREATIC

    17

    HEREDITARY PANCREATIC CANCER PANEL

    Description

    The PreSENTIA hereditary Pancreatic cancer panel tests for numerous inherited genetic mutations that could cause pancreatic cancers in the future. Identifying these mutations empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for pancreatic cancers are those that have:

    • Several family members in the same side of the family with pancreatic cancer
    • Personal or family history of a hereditary cancer syndrome linked to pancreatic cancer
    • A family member that has been diagnosed with a genetic mutation that has pancreatic cancer susceptibility

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    17
    No of related hereditary cancer syndromes:
    9

    Genes Tested

    APC, CDK4, MLH1, SMAD4, ATM, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), MSH2, STK11, BMPR1A, EPCAM, MSH6, TP53, BRCA1, MEN1, PALB2, PMS2, BRCA2

    Hereditary Cancer Syndromes associated with this panel:

    • Hereditary Melanoma-Pancreatic cancer syndrome (CDKN2A, CDK4) (Associated cancers: Melanoma, pancreatic cancer, breast cancer)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) (Associated cancers: Colorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC) (Associated cancers: Gastric, Pancreatic, Colorectal, Osteomas, Small Bowel)
    • Li-Fraumeni syndrome (TP53) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain tumors, Lung, Leukemia)
    • Peutz-Jeghers syndrome (STK11) (Associated cancers: Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A) (Associated cancers: Colorectal, Gastric, Pancreatic)
    • Multiple endocrine neoplasia type 1 (MEN1) (Associated cancers: Thyroid, Parathyroid)
    • Ataxia-Telangiectasia syndrome (ATM) (Associated cancers: Leukemia, lymphoma)

  • RENAL

    13

    PreSENTIA HEREDITARY RENAL CANCER PANEL

    Description

    The PreSENTIA hereditary renal cancer panel tests for numerous genetic mutations that could cause renal (kidney) cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary renal cancers are those that have:

    • Family members that have had renal cancer, especially at a young age
    • Family members with renal cancer in both kidneys
    • Family members diagnosed with a hereditary cancer syndrome associated with renal cancer
    • Personal history of a hereditary cancer syndrome associated with renal cancer
    • Multiple cancers in the same family member
    • A family member with a confirmed genetic mutation associated with hereditary renal cancer.
    • History of previous malignancies

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    13
    No of related hereditary cancer syndromes:
    5

    Genes Tested

    BAP1, TP53, EPCAM, VHL, MLH1, SDHB, MSH2, SDHC, MSH6, SDHD, PMS2, SDHAF2, PTEN

    Hereditary Cancer Syndromes associated with this panel:

    • Von-Hippel Lindau syndrome (VHL) (Associated cancers: Renal, Paraganglioma/Pheochromocytoma)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) (Associated cancers: Colorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal)
    • BAP1 Mutation Associated Disease (BAP1) (Associated cancers: Skin, Eye, Renal, Mesothelioma)
    • PTEN Hamartoma syndrome (PTEN) (Associated cancers: Breast, Endometrial, Colorectal, Melanoma, Renal)
    • Li-Fraumeni syndrome (TP53) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain tumors, Lung, Leukemia)

  • SKIN (XP-ASSOCIATED)

    9

    PreSENTIA HEREDITARY SKIN (XP-ASSOCIATED) CANCER PANEL

    Description

    The PreSENTIA hereditary Xeroderma Pigmentosum-related cancer panel tests for genetic mutations in numerous genes that could cause skin cancers in the future. Identifying mutations in this gene empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for Xeroderma Pigmentosum-related skin cancers are those that have:

    • Family or personal history of a hereditary cancer syndrome associated with skin cancers
    • A family member with a confirmed genetic mutation associated with Xeroderma Pigmentosum

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    9
    No of related hereditary cancer syndromes:
    1

    Genes Tested

    DDB2, ERCC5, ERCC1, POLH, ERCC2, XPA, ERCC3, XPC, ERCC4

    Hereditary Cancer Syndromes associated with this panel:

    • Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XP) (Associated cancers: Non-Melanoma and Melanoma)

  • FAMILIAL MELANOMA

    7

    PreSENTIA HEREDITARY FAMILIAL MELANOMA CANCER PANEL

    Description

    The PreSENTIA hereditary familial melanoma cancer panel tests for numerous genetic mutations that could cause familial melanoma skin cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary melanoma cancers are those that have:

    • At least two first-degree family member who have had metastatic melanoma
    • At least one family member has had multiple melanomas
    • Family or personal history of a hereditary cancer syndrome associated with melanoma
    • A family member with a confirmed genetic mutation associated with hereditary melanoma

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    7
    No of related hereditary cancer syndromes:
    5

    Genes Tested

    BAP1, PTEN, BRCA2, RB1, CDK4, TP53, CDKN2A (CDKN2Ap16(INK4A), CDKN2Ap14(ARF))

    Hereditary Cancer Syndromes associated with this panel:

    • Hereditary Melanoma-Pancreatic cancer syndrome (CDKN2A, CDK4) (Associated cancers: Melanoma, Pancreatic, Breast)
    • Retinoblastoma (RB1) (Associated cancers: Eye, Bone)
    • BAP1 Mutation Associated Disease (BAP1) (Associated cancers: Skin, Eye, Renal, Mesothelioma)
    • PTEN Hamartoma syndrome (PTEN) (Associated cancers: Breast, Endometrial, Colorectal, Melanoma, Renal)
    • Li-Fraumeni syndrome (TP53) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain tumors, Lung, Leukemia)

  • PARAGANGLI­OMA / PHEOCHROMO­CYTOMA

    6

    PreSENTIA HEREDITARY PARAGANGLIOMA / PHEOCHROMOCYTOMA CANCER PANEL

    Description

    The PreSENTIA hereditary Paraganglioma / Pheochromocytoma cancer panel tests for genetic mutations in numerous genes that could cause Paraganglioma or Pheochromocytoma cancer in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for Paraganglioma or Pheochromocytoma cancers are those that have:

    • Family or personal history of a hereditary cancer syndrome associated with paraganglioma / pheochromocytoma cancers
    • A family member with a confirmed genetic mutation associated with hereditary paraganglioma / pheochromatoma cancer

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    6
    No of related hereditary cancer syndromes:
    3

    Genes Tested

    RET, SDHC, SDHAF2, SDHD, SDHB, VHL

    Hereditary Cancer Syndromes associated with this panel:

    • Von-Hippel Lindau syndrome (VHL) (Associated cancers: Renal, Paragangliomas, Pheochromocytomas)
    • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHD, SDHAF2, SDHC, SDHB) (Associated cancers: Renal, Thyroid)
    • Multiple endocrine neoplasia type 2 (RET) (Associated cancers: Thyroid, Pheochromocytoma)

  • PARATHYROID

    1

    PreSENTIA HEREDITARY PARATHYROID CANCER PANEL

    Description

    The PreSENTIA hereditary parathyroid cancer panel tests for numerous genetic mutations that could cause parathyroid cancers in the future. Identifying mutations in these genes empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:

    • At least two first-degree family member who have had parathyroid tumors
    • A personal or family history of a hereditary cancer syndrome associated with parathyroid cancer
    • A family member with a confirmed genetic mutation associated with hereditary parathyroid cancer

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    1
    No of related hereditary cancer syndromes:
    1

    Genes Tested

    MEN1

    Hereditary Cancer Syndromes associated with this panel:

    • Multiple endocrine neoplasia type 1 (MEN1) (Associated cancers: Thyroid, Parathyroid)

  • THYROID

    1

    PreSENTIA HEREDITARY THYROID CANCER PANEL

    Description

    The PreSENTIA hereditary thyroid cancer panel tests for genetic mutations in the RET gene that could cause thyroid cancer in the future. Identifying mutations in this gene empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:

    • At least one first-degree family member who has had thyroid cancer
    • A personal or family history of a hereditary cancer syndrome associated with thyroid cancer
    • A family member with a confirmed genetic mutation associated with hereditary thyroid cancer

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    1
    No of related hereditary cancer syndromes:
    1

    Genes Tested

    RET

    Hereditary Cancer Syndromes associated with this panel:

    • Multiple endocrine neoplasia type 2 (RET) (Associated cancers: Thyroid, Pheochromocytoma)

  • PAN-CANCER

    62

    PreSENTIA HEREDITARY PAN-CANCER PANEL

    Description

    The PreSENTIA hereditary pan-cancer panel tests for 62 inherited genetic mutations that could cause several cancers in the future. Identifying these mutations empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • Family members with an unusual type of cancer (breast cancer in a male)
    • Personal or family history of a hereditary cancer syndrome
    • Personal or family history of a confirmed genetic mutation with known cancer susceptibility
    • History of previous malignancies

    TAT:
    2-3 weeks
    Sample:
    Buccal Swab
    No of Genes Tested:
    62
    No of related hereditary cancer syndromes:
    24

    Genes Tested

    APC, ERCC2, MEN1, RB1, ATM, ERCC3, MLH1, RET, BAP1, ERCC4, MRE11, SDHAF2, BARD1, ERCC5, MSH2, SDHB, BMPR1A, FANCA, MSH6, SDHC, BRCA1, FANCB, MUTYH, SDHD, BRCA2, FANCC, NBN, SLX4, BRIP1, FANCD2, PALB2, SMAD4, CDH1, FANCE, PMS2, SMARCA4, CDK4, FANCF, POLD1, STK11, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), FANCG, POLE, TP53, CHEK2, FANCI, POLH, VHL, DDB2, FANCL, PTEN, XPA, DICER1, FANCM, RAD50, XPC, EPCAM, GREM1, RAD51C, ERCC1, HOXB13, RAD51D,

    Hereditary Cancer Syndromes associated with this panel:

    • Li-Fraumeni syndrome (TP53) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain tumors, Lung, Leukemia)
    • Li-Fraumeni syndrome 2 (CHEK 2) (Associated cancer: Breast, Sarcomas and Brain Tumors)
    • Hereditary Breast & Ovarian cancer syndrome (BRCA1, BRCA2) (Associated cancers: Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC) (Associated cancers: Gastric, Pancreatic, Colorectal, Osteomas, Small Bowel)
    • MUTYH-associated polyposis syndrome (MUTYH) (Associated cancer: Colorectal)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) (Associated cancers: Colorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal)
    • PTEN Hamartoma syndrome (PTEN) (Associated cancers: Breast, Endometrial, Colorectal, Melanoma, Renal)
    • Peutz-Jeghers syndrome (STK11) (Associated cancers: Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A) (Associated cancers: Colorectal, Gastric, Pancreatic)
    • Fanconi Anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C) (Associated cancers: Leukemia, Tumors of the head and neck, Gastrointestinal)
    • Von-Hippel Lindau syndrome (VHL) (Associated cancers: Renal, Paraganglioma/Pheochromocytoma)
    • Retinoblastoma (RB1) (Associated cancers: Eye, Bone)
    • Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XP) (Associated cancers: Non-Melanoma and Melanoma)
    • Hereditary Melanoma-Pancreatic cancer syndrome (CDKN2A, CDK4) (Associated cancers: Melanoma, pancreatic cancer, breast cancer)
    • Hereditary diffuse gastric syndrome (CDH1) (Associated cancers: Gastric, Breast)
    • DICER 1 syndrome (DICER1) (Associated cancers: Lung, Renal, Ovarian, Thyroid cancer
    • Polymerase Proofreading Associated syndrome (POLD1, POLE) (Associated cancers: Colorectal, Endometrial)
    • Multiple endocrine neoplasia type 1 (MEN1) (Associated cancers: Thyroid, Parathyroid)
    • Multiple endocrine neoplasia type 2 (RET) (Associated cancers: Thyroid, Pheochromocytoma)
    • BAP1 Mutation Associated Disease (BAP1) (Associated cancers: Skin, Eye, Renal, Mesothelioma)
    • Ataxia-telangiectasia syndrome (ATM) (Associated cancers: Leukemia, Lymphoma)
    • Hereditary mixed polyposis syndrome (GREM1) (Associated cancer: Colorectal)
    • Constitutional mismatch repair syndrome (MSH2, MSH6, MLH1, PMS2) (Associated cancers: Hematologic malignancies, Brain tumors, Gastrointestinal cancers, Colorectal tumors)
    • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHD, SDHAF2, SDHC, SDHB) (Associated cancers: Renal, Thyroid, Paragangliomas, Pheochromocytomas)

  • Hereditary Cancer Syndromes

    Renal, Paragangliomas, Pheochromocytomas
    Cancer Predisposing Syndromes & Associated Genes Associated Cancers
    Li-Fraumeni syndrome
    TP53
    Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain, Lung, Leukemia
    Li-Fraumeni syndrome 2
    CHEK2
    Breast, Sarcoma, Brain
    Hereditary breast and ovarian cancer syndrome
    BRCA1, BRCA2
    Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus
    Familial adenomatous polyposis/Attenuated familial adenomatous polyposis syndrome
    APC
    Gastric, Pancreatic, Colorectal, Osteomas, Small Bowel
    MUTYH-associated polyposis syndrome
    MUTYH
    Colorectal
    Lynch syndrome
    MLH1, MSH2, MSH6, PMS2, EPCAM
    Colorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal
    PTEN hamartoma syndrome
    PTEN
    Breast, Endometrial, Colorectal, Melanoma, Renal
    Peutz-Jeghers syndrome
    STK11
    Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic
    Juvenile polyposis syndrome
    SMAD4, BMPR1A
    Colorectal, Gastric, Pancreatic
    Fanconi anemia syndrome
    FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C
    Leukemia, Tumors of the head & neck, Gastrointestinal
    Von-Hippel Lindau syndrome
    VHL
    Renal, Paragangliomas, Pheochromocytomas
    Retinoblastoma
    RB1
    Eye &Non-Melanoma & bone
    Xeroderma pigmentosum syndrome
    DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA,XPC
    Non-Melanoma & Melanoma
    Hereditary melanoma-pancreatic cancer syndrome
    CDKN2A, CDK4
    Melanoma, Pancreatic & Breast
    Hereditary diffuse gastric syndrome
    CDH1
    Gastric & Breast
    DICER 1 syndrome
    DICER1
    Lung, Renal, Ovarian, Thyroid
    Polymerase Proofreading Associated syndrome
    POLD1, POLE
    Colorectal & Endometrial
    Multiple Endocrine Neoplasia (MEN) syndrome type 1
    MEN1
    Parathyroid & Pancreatic
    Multiple Endocrine Neoplasia (MEN) syndrome type 2
    RET
    Thyroid & Pheochromocytoma
    BAP1 Mutation associated disease
    BAP1
    Skin, Eye, Kidney, Mesothelioma
    Ataxia-telangiectasia syndrome
    ATM
    Leukemia & Lymphoma
    Hereditary-mixed polyposis syndrome
    GREM1
    Colorectal
    Constitutional mismatch repair syndrome
    MSH2, MSH6, MLH1, PMS2
    Hematologic malignancies, Brain, Gastrointestinal, Colorectal
    Hereditary Paraganglioma – Pheochromocytoma syndrome
    SDHAF2, SDHB, SDHC, SDHD
    Renal, Thyroid, Paragangliomas, Pheochromocytomas

HOW CAN I TAKE PreSENTIA?

  • CONSULT WITH YOUR HEALTHCARE PROVIDER ON WHICH PANEL IS IDEAL FOR YOU
  • YOUR DOCTOR WILL COLLECT A BUCCAL SWAB SAMPLE FROM YOU
  • THE SAMPLE WILL BE SENT TO OUR LABORATORY
  • THE SAMPLE WILL BE ANALYZED IN OUR LABORATORY
  • RESULTS WILL BE SENT TO YOUR HEALTHCARE PROVIDER WITHIN 2-3 WEEKS

FAQ

  • What are mutations?

    A mutation is a change that happens in the DNA that could possibly affect the health of an individual.

  • What is genetic testing?

    Genetic testing identifies changes in the DNA.

  • What is cancer susceptibility and cancer predisposition?

    Cancer susceptibility, or predisposition, is the likelihood of being affected by cancer in the future. This depends on an individual’s DNA. There are certain inherited, genetic changes that raise someone’s risk of developing cancer in the future. This is because these changes happen in genes that are responsible for protecting the body from disease, and when they are affected, their protective role halts.

  • What are germline mutations?

    Germline mutations are changes in the DNA that are inherited from parents to their children. These changes are present from birth in all the cells in the body. Germline mutations are different from somatic mutations, which occur when a genetic change happens in the DNA due to exposure to risk factors – after a person is born. People with germline mutations in a cancer gene have a higher chance of developing cancer in their lifetime. If cancer develops due to a germline mutation, it is called hereditary cancer.

  • What is hereditary screening?

    A hereditary screening test checks if an individual has an inherited, genetic change in a gene with high cancer susceptibility from birth. Identifying the mutation that could cause cancer in the future is useful for people with cancer in their family history, and for people suspected of having a hereditary form of cancer. This knowledge can help with better medical planning and avoiding risk factors.

  • How do I decide what is the best panel for me?

    Your healthcare provider will recommend the best panel for you after considering the types of cancers that have affected your family members, any genetic changes that have already been diagnosed in one of your family members, and any symptoms exhibited. Consult with your healthcare provider on which panel is ideal.

NIPD Genetics - Privacy Policy

General Statement

This Privacy Policy applies only to www.nipd.com and its subdomains (hereafter collectively referred to as “Sites") that link to this policy. NIPD Genetics Sites are owned by NIPD Genetics Public Company Ltd and are operated by NIPD Genetics Public Company Ltd and on occasion by a third-party that is responsible for the technical maintenance of the Sites.

If, you do not agree with this Privacy Policy, please do not access or use any of NIPD Genetics Sites.

NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.

Personal data for purposes of this Privacy Policy, is any information by which you can be individually identified, including, but not limited to, your name, profession, address, e-mail address, and telephone number.

You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
Engomi, Nicosia
2409, Cyprus

NIPD Genetics Data Protection Officer can be reached at dpo@nipd.com

This Privacy Policy applies only to the Sites as defined above and which are operated by NIPD Genetics. The NIPD Genetics Privacy Policy seeks to inform the users of its Sites of the following:

NIPD Genetics will not use or share your information with anyone, except as described in this Privacy Policy. This Privacy Policy does not apply to any information we might collect by other digital and offline means and or from other digital and offline sources. The use of information collected through our Sites shall be limited to the purposes under this Privacy Policy and our Terms of Use to customers.

This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.

We use your data to provide and improve the Sites. By using the Sites, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from www.nipd.com

Type of personal information NIPD Genetics may collect through its Sites

Information Collection And Use

We collect several different types of information for various purposes to provide and improve our Sites and services to you.

Personal Data

While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:

If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.

Cookies and Usage Data

Usage Data

We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

Tracking & Cookies Data

We use cookies and similar tracking technologies to track the activity on our Sites and hold certain information.

Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.

Examples of Cookies we use:

Session Cookies. We use Session Cookies to operate our Sites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the Sites

Keyword cookies. To understand how visitors discover the Sites.

Use of Data

www.nipd.com uses the collected data for various purposes:

Transfer of Data

Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

www.nipd.com will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.

NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:

Security of Data

The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.

Service Providers

We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

Analytics

We may use third-party Service Providers to monitor and analyze the use of our Sites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

Access to your personal data, correction, deletion, and Opting Out

You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer pdo@nipd.com

Links to Other Sites

Our Sites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

Children's Privacy

Our Service does not address anyone under the age of 18 ("Children").

We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.

Changes to This Privacy Policy

We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

Contact Us

If you have any questions about this Privacy Policy, please contact pdo@nipd.com

Ok got it!